Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis

March 26, 2026 updated by: Centre Hospitalier Universitaire de Nice

Psoriasis is a chronic autoimmune disorder of the skin. In this disease, the inflammatory caspases, cysteine proteases involved in the processing of many proteins, are activated. Transgenic mice expressing the cleaved form of caspases by Lyn, a tyrosine kinase Src family, develop an inflammatory syndrome with the characteristics of human psoriasis.

To clarify the relationship between the cleaved form of Lyn by caspases and psoriasis, the investigators intend to develop a clinical study to analyze the expression, cleavage and activity of Lyn and the activation of caspases from skin biopsies of patients with this disease.

This study will be conducted on a cohort of patients with different forms of psoriasis (plaque, pustular and erythrodermic) and atopic dermatitis, another skin disorder associated with chronic inflammation. Thus, the investigators will evaluate the expression and activity of Lyn from skin lesion (L) and non-lesional (NL) from the same patient in parallel with the level of caspase activation and apoptotic inflammatory.

Thus, the investigators will verify that the cleavage by caspases of Lyn is associated specifically with psoriasis, as the investigators believe, or more generally to the skin inflammation. The investigators work would then define the cleavage by caspases of Lyn as a new potential marker of human psoriasis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

170

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Marseille, France, 13 005
        • Assistance Publique - Hopitaux de Marseille
      • Nice, France, 06000
        • University Hospital of Nice
      • Toulouse, France, 31059
        • University Hospital of Toulouse

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Psoriasis arms:

  • Plaque psoriasis and erythrodermic more than 10% of body surface area.

  • Pustular psoriasis of at least 1% of body surface.

    • Atopic dermatitis arm:Patients with atopic dermatitis has been identified and inflammatory lesions on the skin.
    • Healthy arm:People not suffering from any skin disease

Exclusion Criteria:

  • Systemic treatment of psoriasis for at least 4 weeks and / or local treatment for at least 2 weeks at the time of study entry.
  • Patient with significant infection and / or immunocompromised.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: chronic plaque psoriasis
3 biopsies: 2 lesional and 1 non-lesional
Other: 3 Biopsies
3 biopsies: 2 lesional and 1 non-lesional
Other: pustular psoriasis
3 biopsies: 2 lesional and 1 non-lesional
Other: 3 Biopsies
3 biopsies: 2 lesional and 1 non-lesional
Other: erythrodermic psoriasis
3 biopsies: 2 lesional and 1 non-lesional
Other: 3 Biopsies
3 biopsies: 2 lesional and 1 non-lesional
Other: atopic dermatitis
2 biopsies: 1 lesional and 1 non-lesional
Other: 2 biopsies
Other Names:
  • 1 lesional and 1 non-lesional
Other: healthy patients
1 biopsy of healthy skin.
Other: biopsy
1 biopsy ok healthy skin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cleavage of Lyn
Time Frame: 1 day
The cleavage of Lyn will be determined in the different extracts of skin of patients with western blotting using an antibody specific for Lyn recognizing the native form but also the form cleaved by caspases.
1 day
Expression levels of Lyn
Time Frame: 1 day
The expression levels of Lyn and its cleaved form will be quantified using the software MultiGauge. The investigators will also determine the level of activity of Lyn using an antibody directed against the active form phosphorylated. The level of expression of proteins of interest will be reported at the level of protein expression control (ERK2) whose expression does not vary depending on the samples (load control).
1 day
Specific activity of apoptotic caspases 3, 6, 7, 8 and 9, and inflammatory caspases 1, 4, and 5
Time Frame: 1 day
The investigators will determine the specific activity of apoptotic caspases 3, 6, 7, 8 and 9, and inflammatory caspases 1, 4, and 5 test microplate. The principle of this test is based on the use of a specific substrate of caspases coupled to a fluorochrome that fluoresces when it is released after the action of caspase-level target aspartate. The fluorescence emission, which is proportional to the amount of active caspase in the sample is then measured with a fluorometer.
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Development of a monoclonal antibodyspecific for the cleaved form of caspases by Lyn
Time Frame: 1 day
Development of a monoclonal antibody specific for the form cleaved by caspases of Lyn. Once obtained and validated, this tool will be especially useful for immunohistological analysis of Lyn on skin sections from patients with psoriasis. Then we can also analyze which skin cells express preferentially cleaved form of Lyn.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire de Nice

Investigators

  • Study Director: Jean-Paul ORTONNE, PU-PH, Centre Hospitalier Universitaire de Nice
  • Study Chair: Sandrine MARCHETTI, PhD, Institut National de la Santé Et de la Recherche Médicale, France
  • Principal Investigator: Marie-Aleth RICHARD, PU-PH, AP-HM
  • Principal Investigator: Carle PAUL, PU-PH, University Hospital, Toulouse

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2012

Primary Completion (Actual)

July 1, 2016

Study Completion (Actual)

July 1, 2016

Study Registration Dates

First Submitted

January 13, 2012

First Submitted That Met QC Criteria

February 23, 2012

First Posted (Estimated)

February 24, 2012

Study Record Updates

Last Update Posted (Actual)

March 31, 2026

Last Update Submitted That Met QC Criteria

March 26, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 11-API-03

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psoriasis

Clinical Trials on 3 Biopsies

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe